Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK2800528 · 1 trial · 1 indication
An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is associated with liver injury and impaired liver function.
Safety data for laboratory clinical chemistry parameters including albumin, creatinine, glucose, sodium, potassium, chloride, calcium, total protein, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), alkaline phosphatise, total and direct bilirubin, and uric acid will be assessed
Safety data for laboratory hematology parameters including platelet count, red blood cell (RBC) count, absolute white blood cell (WBC) count, reticulocyte count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular haemoglobin concentration (MCHC), mean corpuscular haemoglobin (MCH), neutrophils, lymphocytes, monocytes, eosinophils, and basophils will be assessed.
Safety data for laboratory urinalysis parameters including specific gravity, pH, glucose, protein, blood and ketones by dipstick , and microscopic examination will be assessed
Safety data for vital signs including blood pressure, heart rate, and body temperature will be measured
Supine 12-lead ECG data will be monitored
| Arm | Type | Description |
|---|---|---|
| GSK2800528 Arm | EXPERIMENTAL | Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo. |
| Placebo Arm | PLACEBO_COMPARATOR | Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo. |
| Adalimumab Arm | ACTIVE_COMPARATOR | In Cohort 4, all subjects will receive adalimumab 40 mg (0.8 mL solution) as subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| GSK2800528, solution for injection | DRUG | Drug will be administered at 3 different dose levels by subcutaneous injection. |
| Placebo (0.9% w/v Sodium Chloride), solution for injection | DRUG | Subcutaneous injection of. 0.8 mL solution will be administered |
| Adalimumab, solution for injection | DRUG | Subcutaneous injection of 0.8 mL solution will be administered (40mg) |
Inclusion Criteria: * ALT, alkaline phosphatase and bilirubin \<= 1.5x upper limit of normal (ULN) (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * Average bazett's corrected QT interval (QTcB) \< 450 msec, or QTcB \< 480 msec in subjects with ...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
GSK2800528 is an investigational small molecule developed by GSK plc for psoriasis, a dermatological condition. It is administered as a solution for injection. The compound has been studied in a Phase 1 clinical trial in healthy subjects, and it has not been approved for any use.
GSK2800528 is being developed for the treatment of psoriasis, a skin condition. Its clinical evaluation so far has been limited to a Phase 1 study conducted in healthy volunteers rather than in patients with psoriasis. It remains investigational and is not an approved treatment.
GSK2800528 is developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 1 clinical study of the compound. GSK plc is the sole developer named for this asset.
GSK2800528 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The study was randomized, double-blind, and placebo-controlled, and it enrolled 45 participants. The drug is investigational and has not been approved by the FDA.
GSK2800528 has been evaluated in one completed Phase 1 trial, NCT01899755, titled a study to evaluate the pharmacokinetics, safety and tolerability, immunogenicity, and pharmacodynamics of GSK2800528 in healthy subjects. The trial enrolled 45 participants in the United Kingdom, included both sexes, and required participants to be at least 18 years old.
Yes, GSK2800528 solution for injection refers to the same investigational compound, GSK2800528. The solution for injection describes the injectable formulation of the small molecule developed by GSK plc for psoriasis. Both names point to the same Phase 1 asset.